The mechanisms underlying aneuploidy in multiple myeloma (MM) are unclear.
Introduction
Genomic instability in cancer is broadly categorized into mutational instability (e.g. microsatellite, MIN) and chromosome instability (CIN). CIN, characterized by unstable aneuploidy, is the most common form of genetic instability in human cancer.
Several pathways are operative in the generation of CIN. One pathway involves telomeric dysfunction with chromosome breakage and the presence of dicentric chromosomes. Another pathway involves gains and losses of intact whole chromosomes and is thought to be due to continuous chromosome mis-segregation during mitosis 1, 2 .
This latter phenotype may result from genetic alterations in genes that delay cell entry into anaphase if chromosomes are mis-aligned on the bipolar mitotic spindle such as BUB1, MAD2 and BUBR1 (so called mitotic checkpoint genes) or centrosome amplification 3, 4 . Few examples of mutations in the mitotic checkpoint genes have been documented in human cancers, despite elegant mechanistic studies showing their putative pathogenetic role 5 .
Centrosomes are cellular microtubule-organizing centers whose normal function is crucial for chromosome segregation and cytokinesis during mitosis 6 . The centrosome consists of 2 centrioles that are surrounded by amorphous pericentriolar material (PCM).
The centrosome is duplicated only once during the cell cycle to give rise to 2 centrosomes that function as spindle poles of the dividing cell. Extra copies (aberrant) of the centrosome frequently result in formation of multi-polar spindles and inevitably chromosome mis-segregation and aneuploidy [7] [8] [9] [10] .
Centrosome amplification is characterized by combinations of increase in number, size, abnormal structure and function. Centrosome amplification has been detected in a broad range of solid tumors 2, [11] [12] [13] [14] [15] [16] and more recently in leukemia 17, 18 and lymphoma [19] [20] [21] .
In solid tumors, the centrosome abnormalities are associated with advancing stages of the disease, aneuploidy and an aggressive clinical course 2, 11, [13] [14] [15] . The existence of centrosome abnormalities in pre-invasive carcinomas suggests they are early events in cellular transformation 22, 23 .
Multiple myeloma (MM) is characterized almost universally by aneuploidy 24 ,
although it is more evident in the 40%-50% of hyperdiploid cases. Multiple trisomies and monosomies can be observed in the clonal cells. Aneuploidy evolution is still evident at
For personal use only. on October 22, 2017 . by guest www.bloodjournal.org From all stages of the disease since there is heterogeneity in the number of cells harboring any specific aneuploid chromosomes. The mechanisms leading to this aneuploidy are at present unclear. The presence of defined stages of progression from monoclonal gammopathy of undetermined significance (MGUS) to symptomatic MM provides an ideal model for the study disease pathogenesis and evolution. In this study, we investigated the role of centrosome amplification in the pathogenesis of aneuploidy in MM. To do so, we used a combined immunofluorescent (IF) staining and gene expression approach. We showed that centrosomes are not only present in the majority of clonal plasma cells (PCs), but that they are absent in most normal PCs. In addition, centrosome amplification is present in MGUS, suggesting that centrosome amplification occurs early in myelomagenesis. Clinically, patients with high levels of centrosome amplification have short survival. 
IF staining and slide analysis
Bone marrow samples were subjected to red cell lysis using ammonium chloride following which the sample was centrifuged, washed, and a cell count performed.
Cytospin slides were prepared using 75,000 cells per slide and air dried for a minimum of 24 hours. Extra slides were archived at -20°C for future use. Slides were then fixed in -20°C methanol for 5 minutes and place in APK (phosphate buffered detergent) for 5 minutes. 100 μL of blocking buffer (PBS with 5% normal goat serum and 0.1% BSA)
was then added to each slide and incubated for 15 minutes at room temperature. After incubation, the blocking buffer was poured off and the slide blotted dry before 100 μL of diluted (1:500) hCen2.4 ascites antibody (generous gift from Dr JL Salisbury, Mayo
Clinic Rochester, MN, USA) was applied. The slides were then incubated for 30 minutes at room temperature before being washed with APK 3 times (3 minutes/wash) using gentle agitation. The slides were wiped dry and 100 μL (2ug/ml) of diluted (1:1000) goat anti mouse IgG F(ab') 2 -Alexa 488 added (Molecular Probes, Eugene, OR). Further 
Gene expression profiling (GEP)
Gene expression analysis was performed on CD138 + selected PCs RNA using the Affymetrix U133A chip (Affymetrix, Santa Clara, CA). RNA isolation, purification and microarray hybridization has been previously reported 27 . Gene expression intensity values were log transformed, normalized to the median and analyzed using GeneSpring 7
(Agilent Technologies, Palo Alto, CA). 
cIg-FISH
cIg-FISH was performed on group 2 patients as previously described 29 . We used probes previously described by us for the detection of 13q deletion (Δ 13) and translocations involving the immunoglobulin heavy chain (IgH) locus using the 'break apart' strategy 30 . In addition, for group 2 patients, commercially available direct-labeled chromosome enumeration probe (CEP) for chromosomes 3, 9, 11 and 15 (Vysis Inc.
Downers Grove, IL USA) and a direct labeled BAC clone for the p-arm of chromosome
(RPCI 11 88I12, BACPAC Resources, Children's Hospital Oakland Research
Institute, Oakland, CA) were used to detect chromosomal aneusomy and to assign ploidy status based on an index highly specific for hyperdiploidy 31 . Aneusomy is present if more than 10% of PCs have 3 or more signals or only 1 signal for each CEP probe.
DNA index by flow cytometry
Ploidy for group 1 patients was assessed by flow cytometry. The total DNA content was analyzed by dual channel flow cytometric using propidium iodide to measure the DNA content and kappa and lambda light chain anti-sera to identify the clonal cells as previously described 32 .The ploidy subtypes are defined as followed: DNA index 1.06 to 1.74 hyperdiploid; DNA index <1.06 or > 1.74 non-hyperdiploid.
Plasma cell labeling index (PCLI)
The bone marrow PCLI, which reflects proliferative activity of PCs was determined using a slide-based IF method as previously described 33 .
Statistical analysis
The Mann-Whitney U test or the student's t test was used to compare continuous variables. For comparison of multiple groups, the Kruskal-Wallis test was used with Dunn's multiple testing correction for pair-wise comparisons. Correlation was measured using the Spearman correlation coefficient. Categorical variables were compared using the Fisher's exact test. The distribution for overall survival (OS) was estimated using the method of Kaplan and Meier. The log-rank test was used to test for differences in survival between groups. OS was calculated from the date of diagnosis to death. Cox 
Results

Centrosome amplification is common in all stages of PC neoplasm since MGUS
The pattern of centrin staining was different between PCs from normal donors and patients with monoclonal gammopathies (Figure 1A-H 
Gene expression analysis of centrosome protein genes
Together with centrin, pericentrin and γ-tubulin are also major centrosome protein and components of the PCM 9, 34 . We assessed the expression levels of genes encoding these proteins in group 2 patients. The expression of these genes were significantly correlated and increased progressively from MGUS to MM (Figure 3, Table 1 ), similar to results from other studies which showed concordant results when these different proteins are stained 13, 17 . We then calculated a gene expression based centrosome index 
Centrosome amplification and aneuploidy
To see if centrosome abnormalities increase with aneuploidy, the number of aneusomic chromosomes was correlated with the CI. In 97 group 2 MM patients, no correlation between the number of aneuploid chromosomes as detected by FISH and the centrosome index was demonstrated (data not shown).
MM Patients with high centrosome index has poor prognostic features and survival
Next, we investigated the clinical significance of centrosome amplification in the cohort of 97 group 2 MM patients. High CI (CI > 4) is associated with established poor prognostic features such as Δ13, high PCLI (>1%). Limited information also allowed us to find more extreme centrosome amplification (CI>4) among patients with 4p16+MAF compared to other TC groups. However, there was no difference in the distribution of CI across the International Staging System (ISS) stages ( Table 2) . When treated as a continuous variable, the PCLI was also significantly higher in patients with high CI 
Discussion
In this comprehensive study of centrosome abnormalities in PC neoplasm using IF for protein expression and GEP, we have shown that centrosome amplification is present since MGUS suggesting it plays an early role in genomic instability and myeloma pathogenesis. Our results obtained with gene expression analysis suggest good concordance between protein and gene expression data. This allows us to derive a geneexpression based CI that is highly correlated with the presence of centrosome amplification. Clinically, a high CI is associated with poor prognostic features and a very short survival.
Centrosome expression is different between normal and malignant PCs
Using IF detection of centrin, an integral centrosome protein associated with and required for the duplication of centrioles 26 , we showed for the first time that most normal PCs do not have centrosome. This is consistent with the notion that normal PCs are generally recognized as terminally differentiated non-dividing cells 31 . In contrast, most malignant PCs have centrosomes. The finding indicates that centrosomes are either retained in the initial steps of malignant transformation of PCs or that centrosome reactivation occurs as an integral part of the oncogenesis in MM. As reactivation of centrosome as a consequence of malignant transformation has never been reported, we believe it is most likely that malignant transformation of PCs occurs prior to loss of centrosomes. An indirect conclusion would be that in most cases of MM, the majority of the cells that form the MM clone have replicative potential (i.e. those with centrosomes).
While this study cannot demonstrate the long-term viability of such cells and thus disprove the theory of a MM stem cell, it certainly argues strongly in favor of the aforementioned replicative potential of malignant PCs. This is consistent with the data generated by the xenograft models reported by Epstein and colleagues 35 .
Centrosome Amplification is observed in MGUS
Centrosome amplification detected by IF is prevalent since MGUS confirming in a larger number of patients, a previous report showing frequent centrosome abnormalities 16, 17, 22 . This is further substantiated by the fact that the percentage of plasma cells with centrosome amplification increases through stages of clonal PC expansion. Although a possible explanation for these differences could be the dilution of clonal cells with polyclonal cells in samples from MGUS and SMM patients, our use of concurrent cIg staining to identify clonotypic plasma cells should minimize this. These results are in agreement with studies in solid tumors that showed higher level of centrosome abnormalities in more advance disease 2, [12] [13] [14] [15] [16] [17] 19 .
Centrosome amplification and aneuploidy
Chromosomal abnormalities and aneuploidy is pervasive in MM. As the 2 main ploidy subtypes of MM differ with regards to the predominant karyotypic abnormalities:
whole chromosome gains and losses for hyperdiploid MM and structural abnormalities including translocations for non-hyperdiploid MM 37 , we hypothesized that the prevalence of centrosome abnormalities may differ between the 2 subtypes (being more common in hyperdiploid MM). However, no difference in centrosome abnormalities was detected. This suggest that although the spectrum of defining genetic abnormalities are different between the 2 ploidy categories of MM, centrosome amplification is involved in mediating ongoing genomic instability in both instances. In particular it should be noted that aneuploidy is also evident in the non-hyperdiploid MM, predominantly based on the presence of monosomies, although trisomies may also be present.
In addition, no correlation between the CI and number of aneusomies from a panel of 5 chromosomes as detect by FISH was found. This may be due to the extensive and complex cytogenetic abnormalities in MM. Most karyotypes contain more than 5 abnormalities and the aneusomies may involve any of the chromosomes. Therefore the panel used in our study may be too limited. Karyotypic analysis would be best but it is well known that informative karyotypes are obtained in only about one sixth of patients
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High CI is associated with poor prognostic features and short survival.
Clinically, patients with a high CI is associated with poor prognostic features like t(4;14), t(14;16), Δ13 and high PCLI and very short survival. Of note, a high CI is associated with poor outcome independent of these other factors. Centrosome amplification and cell cycle deregulation are closely linked. Therefore, tumors with high CI may be more genomically unstable, have greater proliferative potential and are associated with more aggressive subtypes of MM.
Conclusion
In conclusion, we have shown that centrosome amplification in PC neoplasm is common since MGUS and is therefore an early event in myelomagenesis and is probably integral to disease pathogenesis and genomic instability in MM. In MM patients, a high CI is associated with poor prognostic genetic subtypes and portends a short survival.
Further work to establish mechanism underlying centrosome amplification and its connection to cell cycle deregulation may identify potential therapeutic targets. Table 3 . Clinical characteristics of newly diagnosed group 2 MM patients included in survival analysis (n = 67). 
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